GRAIL Shares Top $100 Ahead of FDA Panel Review for Galleri Cancer Test

GRAIL Inc. (GRAL) shares climbed back above $100 on September 22, 2026, as the company prepares for a pivotal FDA advisory panel review of its Galleri multi-cancer early detection test scheduled for September 23, 2026. The FDA panel's verdict could determine the regulatory path for Galleri, GRAIL's flagship blood-based screening product designed to detect multiple cancer types before symptoms appear. A favorable recommendation would mark a significant milestone for the company's commercialization strategy. Investors are positioning ahead of the decision, with the stock's recovery above the $100 threshold reflecting heightened expectations. The panel outcome is expected to drive near-term volatility in GRAL shares regardless of direction.